[Source: TGen] – The Translational Genomics Research Institute (TGen) and Scottsdale Healthcare are testing a new drug specifically for thymic cancer based on early promising results at Scottsdale Healthcare.
PHA-848125AC is produced by Nerviano Medical Sciences of Milan, Italy’s largest pharmaceutical research and development facility. It is designed to stop abnormal cell division and duplication, a common feature of cancer.
For more information: New international study targets rare cancer bringing hope for advanced thymic cancer patients